



- (51) **International Patent Classification:**
C12Q 1/68 (2006.01) *G01N 33/15* (2006.01)
- (21) **International Application Number:**
PCT/CN2011/076187
- (22) **International Filing Date:**
23 June 2011 (23.06.2011)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (71) **Applicant (for all designated States except US):** **CHANG GUNG MEDICAL FOUNDATION CHANG GUNG MEMORIAL HOSPITAL AT KEELUNG** [CN/CN]; No. 222 Maijin Rd., Anle Dist., Keelung City 204, Taiwan (CN).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **CHUNG, Wen-Hung** [CN/CN]; 3F., No. 204, Changgengyihu Vil., Guishan Township, Taoyuan County 333, Taiwan (CN). **HUNG, Shuen-Iu** [CN/CN]; 3F., No. 204, Changgengyihu Vil., Guishan Township, Taoyuan County 333, Taiwan (CN).
- (74) **Agent:** **WANG & ASSOCIATES**; Suite 1808A, Building 1, No. 16 Chaoyangmenwai Street, Chaoyang District, Beijing 100020 (CN).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) **Title:** RISK ASSESSMENT FOR PHENYTOIN-INDUCED ADVERSE DRUG REACTIONS




FIG. 2

(57) **Abstract:** ABSTRACT A method of predicting the risk of a patient for developing phenytoin-induced adverse drug reactions (ADRs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), or drug reactions with eosinophilia and systemic symptoms (DRESS) is disclosed. Genetic polymorphisms of CYP2C genes (including CYP2C9, CYP2C19, CYP2C8 and CYP2C18), HLA alleles (including HLA-A*0207, HLA-A*2402, HLA-B*1301, HLA-B*1502, HLA-B*4001, HLA-B*4609, HLA-B*5101, HLA-DRB1*1001 or HLA-DRB1*1502) and phenytoin concentration in the patient's plasma can all contribute to phenytoin-induced ADRs.